MHRA Approves Lurbinectedin Combo for Lung Cancer

MHRA authorized lurbinectedin in combination with atezolizumab as maintenance treatment for extensive-stage small cell lung cancer on 23 September 2026 — not by running its own full review of the underlying trial data, but by recognizing a decision the European Commission had already made. It is a clean, current example of how the UK's International Recognition Procedure is actually working two years into its life: a UK approval that arrives faster because MHRA is relying on someone else's finished homework, not because it skipped the homework.

What the International Recognition Procedure actually buys

Since Brexit, MHRA has had to decide, drug by drug, whether to run a fully independent UK assessment or to lean on the work of a trusted reference regulator. The International Recognition Procedure formalizes the second option along two tracks. Route A is for a marketing authorisation application submitted to MHRA within 60 days of the reference regulator's decision, with a target review around 60 days. Route B, used for lurbinectedin plus atezolizumab, applies outside that window and targets roughly 110 days — still meaningfully faster than MHRA's national assessment route, which typically runs closer to a year. Here, the reference decision was the European Commission's approval of the same combination as first-line maintenance therapy for ES-SCLC across the EU, following CHMP's 27 March 2026 positive opinion.

What the trial showed

The regulatory case rests on IMforte, a randomized, open-label Phase 3 trial of 483 adults with ES-SCLC whose disease had not progressed after induction therapy. Patients were assigned to maintenance lurbinectedin plus atezolizumab or to atezolizumab alone. Per MHRA's own summary of the evidence, median overall survival favored the combination: 13.2 months versus 10.6 months. Progression-free survival showed a larger relative gap: 5.4 months versus 2.1 months. ES-SCLC has a poor prognosis and historically few maintenance options once a patient responds to first-line chemoimmunotherapy, which is the gap this approval is aimed at closing.

Why the pathway is the story

Lurbinectedin is not a new molecule to regulators generally: single-agent lurbinectedin already holds US accelerated approval for previously treated metastatic SCLC, dating to 2020. What is new here is watching IRP Route B do exactly what it was built to do — take a decision the EU had already reached, on a combination already used elsewhere, and turn it into a UK marketing authorisation in a matter of months rather than the better part of a year. For regulatory teams sequencing multi-market filings, that is the operational lesson: a UK filing timed to follow shortly after an EU or other reference-regulator approval, rather than run in parallel with it, can now be the faster route to UK market access, not the slower one.

Frequently asked questions

What did MHRA approve on 23 September 2026?

Lurbinectedin plus atezolizumab as maintenance treatment for adults with extensive-stage small cell lung cancer whose disease has not progressed after first-line induction with atezolizumab, carboplatin and etoposide.

What is the International Recognition Procedure?

MHRA's post-Brexit reliance pathway. Route B, used here, recognizes a marketing authorisation already granted by a reference regulator and targets a review of around 110 days.

Which regulator's decision did MHRA rely on?

The European Medicines Agency's, via the European Commission's approval that followed CHMP's 27 March 2026 positive opinion for the same combination.

What evidence supported the approval?

The Phase 3 IMforte trial (483 patients): median overall survival of 13.2 vs 10.6 months and progression-free survival of 5.4 vs 2.1 months, favoring the combination over atezolizumab alone.